Upgrade to SI Premium - Free Trial

Oruka Therapeutics (ORKA)

60.14 -2.14 (3.44%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/11/26 *Est.)

Latest Headlines

Form 8-K Oruka Therapeutics, Inc. For: Jun 02 June 4, 2026 4:16 PM - SEC Filing Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: Dambkowski Carl June 3, 2026 4:53 PM - SEC Filing Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: Kulkarni Samarth June 3, 2026 4:51 PM - SEC Filing Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: Martin Christopher Nathan June 3, 2026 4:49 PM - SEC Filing Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: BALL KRISTINE M June 3, 2026 4:48 PM - SEC Filing Form 4 Oruka Therapeutics, Inc. For: Jun 02 Filed by: Fairmount Funds Management LLC June 3, 2026 4:45 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Oruka Therapeutics (ORKA) June 3, 2026 6:51 AM - StreetInsider Piper Sandler on Oruka Therapeutics (ORKA): 'We remain bullish into a catalyst-rich year+' June 2, 2026 8:26 AM - StreetInsider Oruka Therapeutics expands license agreement to include IBD indication June 1, 2026 4:05 PM - StreetInsider Form 8-K Oruka Therapeutics, Inc. For: May 29 June 1, 2026 4:03 PM - SEC Filing Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation May 28, 2026 8:35 AM - StreetInsider Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference May 28, 2026 8:00 AM - StreetInsider Form 4 Oruka Therapeutics, Inc. For: May 21 Filed by: Dambkowski Carl May 22, 2026 4:54 PM - SEC Filing Form 144 Oruka Therapeutics, Inc. Filed by: Dambkowski Carl May 21, 2026 4:32 PM - SEC Filing Form 4 Oruka Therapeutics, Inc. For: May 18 Filed by: Agarwal Arjun May 18, 2026 6:08 PM - SEC Filing Form 144 Oruka Therapeutics, Inc. Filed by: Agarwal Arjun May 18, 2026 4:35 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Oruka Therapeutics (ORKA) May 18, 2026 7:03 AM - StreetInsider Form 4 Oruka Therapeutics, Inc. For: May 15 Filed by: Goncalves Joana May 15, 2026 8:17 PM - SEC Filing Form SCHEDULE 13G/A Oruka Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP May 15, 2026 5:52 PM - SEC Filing Oruka Therapeutics (ORKA) Misses Q1 EPS by 48c May 13, 2026 4:16 PM - StreetInsider Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update May 13, 2026 4:03 PM - Globe NewsWire Form 10-Q Oruka Therapeutics, Inc. For: Mar 31 May 13, 2026 4:02 PM - SEC Filing Halozyme partners with Oruka for psoriasis drug development deal May 6, 2026 8:01 AM - StreetInsider Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology May 6, 2026 8:00 AM - PR NewsWire Form SCHEDULE 13D/A Oruka Therapeutics, Inc. Filed by: Fairmount Funds Management LLC May 4, 2026 6:01 PM - SEC Filing Form 4 Oruka Therapeutics, Inc. For: May 01 Filed by: Sandler Laura Lee May 1, 2026 6:26 PM - SEC Filing Form 144 Oruka Therapeutics, Inc. Filed by: Sandler Laura Lee May 1, 2026 4:43 PM - SEC Filing Form 8-K Oruka Therapeutics, Inc. For: Apr 27 April 30, 2026 4:22 PM - SEC Filing Form 424B5 Oruka Therapeutics, Inc. April 29, 2026 4:56 PM - SEC Filing Oruka Therapeutics (ORKA) PT Raised to $120 at H.C. Wainwright April 29, 2026 6:57 AM - StreetInsider Oruka Therapeutics prices $700 million public offering at $72.50 per share April 28, 2026 7:43 PM - StreetInsider Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering April 28, 2026 7:43 PM - Globe NewsWire Oruka Therapeutics (ORKA) PT Raised to $100 at UBS April 28, 2026 8:23 AM - StreetInsider Form 424B5 Oruka Therapeutics, Inc. April 27, 2026 5:23 PM - SEC Filing Form 424B5 Oruka Therapeutics, Inc. April 27, 2026 5:23 PM - SEC Filing Oruka Therapeutics announces $500 million public stock offering April 27, 2026 4:17 PM - StreetInsider Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering April 27, 2026 4:17 PM - Globe NewsWire Oruka Therapeutics (ORKA) PT Raised to $131 at Clear Street April 27, 2026 4:12 PM - StreetInsider Oruka Therapeutics (ORKA) PT Raised to $200 at Guggenheim April 27, 2026 11:24 AM - StreetInsider Oruka Therapeutics (ORKA) PT Raised to $160 at Barclays April 27, 2026 10:54 AM - StreetInsider Oruka Therapeutics (ORKA) PT Raised to $165 at Wedbush April 27, 2026 10:10 AM - StreetInsider Oruka Therapeutics (ORKA) PT Raised to $151 at BTIG April 27, 2026 10:06 AM - StreetInsider Oruka Therapeutics (ORKA) PT Raised to $150 at Stifel April 27, 2026 9:36 AM - StreetInsider Form 8-K Oruka Therapeutics, Inc. For: Apr 27 April 27, 2026 8:01 AM - SEC Filing Oruka Therapeutics (ORKA) PT Raised to $133 at Jefferies April 27, 2026 7:54 AM - StreetInsider Stifel on Oruka Therapeutics (ORKA): 'We expect shares to trade meaningfully-higher' April 27, 2026 7:17 AM - StreetInsider Oruka Therapeutics reports positive psoriasis trial data for ORKA-001 April 27, 2026 7:00 AM - StreetInsider Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis April 27, 2026 7:00 AM - Globe NewsWire Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026 April 26, 2026 12:00 PM - StreetInsider Form 424B7 Oruka Therapeutics, Inc. April 21, 2026 4:23 PM - SEC Filing TD Cowen on Oruka Therapeutics (ORKA): '39-49% Or Higher PASI 100 Should Unlock Multi-Billion Sales' April 20, 2026 8:51 AM - StreetInsider Form ARS Oruka Therapeutics, Inc. For: Dec 31 April 17, 2026 4:21 PM - SEC Filing Form DEFA14A Oruka Therapeutics, Inc. April 17, 2026 4:15 PM - SEC Filing Form DEF 14A Oruka Therapeutics, Inc. For: Jun 02 April 17, 2026 4:11 PM - SEC Filing Form 4 Oruka Therapeutics, Inc. For: Apr 15 Filed by: Goncalves Joana April 15, 2026 6:46 PM - SEC Filing Form 144 Oruka Therapeutics, Inc. Filed by: Goncalves Joana April 15, 2026 4:55 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Oruka Therapeutics (ORKA) April 15, 2026 7:19 AM - StreetInsider Oruka Therapeutics (ORKA) PT Raised to $70 at H.C. Wainwright April 13, 2026 6:39 AM - StreetInsider Form EFFECT Oruka Therapeutics, Inc. April 13, 2026 6:05 AM - SEC Filing Oruka Therapeutics (ORKA) PT Raised to $78 at BTIG April 13, 2026 5:51 AM - StreetInsider Stifel stays Buy on Oruka Therapeutics (ORKA) after Ph2a data from EVERLAST-A study April 8, 2026 4:42 PM - StreetInsider UBS Reiterates Buy Rating on Oruka Therapeutics (ORKA) Following Data Readout April 6, 2026 9:27 AM - StreetInsider Oruka Therapeutics (ORKA) PT Raised to $125 at Guggenheim April 6, 2026 6:38 AM - StreetInsider Oruka Therapeutics (ORKA) files $1B mixed shelf April 2, 2026 4:11 PM - StreetInsider Form S-3 Oruka Therapeutics, Inc. April 2, 2026 4:07 PM - SEC Filing Form SCHEDULE 13G/A Oruka Therapeutics, Inc. Filed by: VANGUARD GROUP INC March 27, 2026 11:07 AM - SEC Filing Oruka Therapeutics (ORKA) PT Raised to $109 at Leerink Partners March 26, 2026 6:23 AM - StreetInsider Piper Sandler on Oruka Therapeutics (ORKA): 'Now Is the Time to Own the Name' March 24, 2026 8:56 AM - StreetInsider Form 4 Oruka Therapeutics, Inc. For: Mar 16 Filed by: Klein Lawrence Otto March 17, 2026 4:11 PM - SEC Filing Form 4 Oruka Therapeutics, Inc. For: Mar 16 Filed by: Agarwal Arjun March 17, 2026 4:10 PM - SEC Filing Form 4 Oruka Therapeutics, Inc. For: Mar 16 Filed by: Sandler Laura Lee March 17, 2026 4:08 PM - SEC Filing Form 4 Oruka Therapeutics, Inc. For: Mar 16 Filed by: Goncalves Joana March 17, 2026 4:07 PM - SEC Filing Form 4 Oruka Therapeutics, Inc. For: Mar 16 Filed by: Quinlan Paul T March 17, 2026 4:06 PM - SEC Filing BTIG Reiterates Buy Rating on Oruka Therapeutics (ORKA): 'Commercial Precedents Continue to Read Through Positively to ORKA-001/2' March 13, 2026 9:26 AM - StreetInsider Oruka Therapeutics (ORKA) PT Raised to $50 at Barclays March 13, 2026 3:25 AM - StreetInsider Oruka Therapeutics (ORKA) PT Raised to $72 at Stifel March 12, 2026 5:53 PM - StreetInsider Oruka Therapeutics (ORKA) Misses Q4 EPS by 45c March 12, 2026 5:19 PM - StreetInsider Form S-8 Oruka Therapeutics, Inc. March 12, 2026 4:26 PM - SEC Filing Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update March 12, 2026 4:05 PM - Globe NewsWire Form 10-K Oruka Therapeutics, Inc. For: Dec 31 March 12, 2026 4:04 PM - SEC Filing Full Article List